Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features ; volume:12 ; number:1 ; day:11 ; month:2 ; year:2010 ; pages:1-9 ; date:2.2010
Breast cancer research ; 12, Heft 1 (11.2.2010), 1-9, 2.2010
- Creator
-
Tung, Nadine
- Contributor
-
Wang, Yihong
Collins, Laura C.
Kaplan, Jennifer
Li, Hailun
Gelman, Rebecca
Comander, Amy H.
Gallagher, Bridget
Fetten, Katharina
Krag, Karen
Stoeckert, Kathryn A.
Legare, Robert D.
Sgroi, Dennis
Ryan, Paula D.
Garber, Judy E.
Schnitt, Stuart J.
SpringerLink (Online service)
- DOI
-
10.1186/bcr2478
- URN
-
urn:nbn:de:1111-201603247460
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tung, Nadine
- Wang, Yihong
- Collins, Laura C.
- Kaplan, Jennifer
- Li, Hailun
- Gelman, Rebecca
- Comander, Amy H.
- Gallagher, Bridget
- Fetten, Katharina
- Krag, Karen
- Stoeckert, Kathryn A.
- Legare, Robert D.
- Sgroi, Dennis
- Ryan, Paula D.
- Garber, Judy E.
- Schnitt, Stuart J.
- SpringerLink (Online service)
Other Objects (12)
Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers
Transactivation of the estrogen receptor promoter by BRCA1
Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
Cisplatin in breast cancer treatment in BRCA1 carriers
Folic acid and cancer risk in BRCA1 carriers
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers
Survival in Norwegian BRCA1 mutation carriers with breast cancer
Selenium and the risk of cancer in BRCA1 carriers
Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers
Transactivation of the estrogen receptor promoter by BRCA1
Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
Cisplatin in breast cancer treatment in BRCA1 carriers
Folic acid and cancer risk in BRCA1 carriers
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers
Survival in Norwegian BRCA1 mutation carriers with breast cancer
Selenium and the risk of cancer in BRCA1 carriers
Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers
Transactivation of the estrogen receptor promoter by BRCA1
Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
Cisplatin in breast cancer treatment in BRCA1 carriers
Folic acid and cancer risk in BRCA1 carriers
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers
Survival in Norwegian BRCA1 mutation carriers with breast cancer